Evidence map›Paper›PMID 30488099›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2019

Clinical impact of

Julian Müller, Daniela A Ferraro, Urs J Muehlematter, Helena I Garcia Schüler, Sarah Kedzia, Daniel Eberli, Matthias Guckenberger, Stephanie G C Kroeze, Tullio Sulser, Daniel M Schmid and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Patterns of disease detection using [European journal of nuclear medicine and molecular imaging · 2021
    Trial
  5. Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Trial
  6. Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Changes in Management AfterJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  15. PSMA PET in Imaging Prostate Cancer.Frontiers in oncology · 2022
    Review
  16. Article
  17. Focal unspecific bone uptake on [European journal of nuclear medicine and molecular imaging · 2021
    Article
  18. Article
  19. Article
  20. Evaluation of [EJNMMI research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

Julian MüllerDepartment of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
Daniela A FerraroDepartment of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
Urs J MuehlematterDepartment of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
Helena I Garcia SchülerDepartment of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Sarah KedziaDepartment of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
Daniel EberliDepartment of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Stephanie G C KroezeDepartment of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Tullio SulserDepartment of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Daniel M SchmidDepartment of Urology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
Aurelius OmlinDepartment of Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Alexander MüllerDepartment of Urology, Spital Limmattal, Schlieren, Switzerland.
Thomas ZilliDepartment of Radiation Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Hubert JohnDepartment of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
Helmut KranzbuehlerDepartment of Radiation Oncology, Stadtspital Triemli, Zürich, Switzerland.
Philipp A KaufmannDepartment of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
Gustav K von SchulthessDepartment of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland.
Irene A BurgerDepartment of Nuclear Medicine, University Hospital Zürich, University of Zürich, Rämistrasse 100, 8091, Zürich, Switzerland. Irene.burger@usz.ch.ORCID http://orcid.org/0000-0001-8029-8692
University of Zurich · CHHôpital Beau-Séjour · CHKantonsspital Winterthur · CHSpital Limmattal · CHTriemli Hospital · CHUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe fast-increasing use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) ligand for the imaging of prostate cancer (PCA) biochemical recurrence has led to a rapid change in treatment concepts. Since the superiority of

methodsOf 327 patients imaged, 223 were referred for recurrent PCA and gave written informed consent for further analysis of their data for this retrospective consecutive cohort analysis. Twenty patients were lost to further follow-up. The rate of detection of recurrence by

results

conclusionThe high rate of recurrence detection by PSMA PET was confirmed and PSMA PET led to a change in management in 60% of patients. Focal therapy for PSMA-positive lesions is a promising approach with complete responses in 45% of patients.

Indexed as

OligopeptidesPositron-Emission TomographyAgedAged, 80 and overEdetic AcidGallium IsotopesGallium RadioisotopesHumansImage Processing, Computer-AssistedMaleMiddle AgedNeoplasm MetastasisProstate-Specific AntigenProstatic NeoplasmsRecurrenceRetrospective StudiesEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesProstate-Specific AntigenBiochemical recurrenceChange in managementDetection rateProstate cancerPSMATargeted

Identifiers

PMID30488099
OpenAlexW2903357641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.